Key result
Statin plus ACEI/ARB therapy is linked to ~34% lower major events in COPD patients.
Why the study?
Do statins, ACE inhibitors, and ARBs reduce cardiovascular events and pulmonary morbidity in patients with COPD?
Population
COPD patients in two cohorts: 1) high cardiovascular risk and 2) low cardiovascular risk.
Comparison
Statins, ACE inhibitors, and ARBs. vs Non-use of these medications.
Design
Case-control
Authors
Loading...
The combination of statins and ACE inhibitors or ARBs is associated with significantly reduced COPD hospitalizations and total mortality in COPD patients regardless of baseline cardiovascular risk.
Case-Control
Do statins, ACE inhibitors, and ARBs reduce cardiovascular events and pulmonary morbidity in patients with COPD?
Relative Risk: 0.66 (95% CI 0.51–0.85)
The combination of statins and ACE inhibitors or ARBs is associated with significantly reduced COPD hospitalizations and total mortality in COPD patients regardless of baseline cardiovascular risk.
Mancini et al. (2006) conducted a case-control in Chronic obstructive pulmonary disease (COPD). Statins combined with ACE inhibitors or ARBs was evaluated on COPD hospitalization, MI, and total mortality (RR 0.66, 95% CI 0.51 to 0.85). The combination of statins and ACE inhibitors or ARBs reduced total mortality in high CV risk (RR 0.42; 95% CI 0.33-0.52) and low CV risk (RR 0.36; 95% CI 0.28-0.45) COPD patients.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: